You have 9 free searches left this month | to do more

duvelisib

Duvelisib is a drug used to treat Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, and other conditions. Duvelisib is being actively studied in 22 studies and prior, has been studied in 3.

Top SponsorsTop SitesTop Investigators
SecuraBioWashington University School of MedicineEdmund Waller
Washington University School of MedicineDana Farber Cancer InstituteDavid Bond, MD
AbbVieMemorial Sloan Kettering Cancer CenterGlenn J. Hanna
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
2021-09-23
Sep 23, 2021
W
Recruiting
  • COVID-19
  • Duvelisib
  • +2 more
  • Saint Louis, Missouri
  • +1 more
2021-05-21
May 21, 2021
W
Not yet recruiting
  • Non-hodgkin Lymphoma
  • Acute Lymphocytic Leukemia
  • Duvelisib
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-09-03
Sep 3, 2021
J
Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-08-10
Aug 10, 2021
N
Completed
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-05-12
May 12, 2021
W
Recruiting
  • T-Cell Lymphoma
  • Indolent B-Cell Lymphoma
  • Duvelisib
  • Peripheral blood draw
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-06-15
Jun 15, 2021
C
Recruiting
  • Follicular Lymphoma
  • Duvelisib
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
2021-01-10
Jan 10, 2021
C
Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duvelisib
  • Duarte, California
  • +2 more
2021-08-13
Aug 13, 2021
S
Suspended
  • Head and Neck Squamous Cell Carcinoma
  • duvelisib
  • pembrolizumab
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-03-15
Mar 15, 2021
S
Terminated
  • Follicular Lymphoma
  • Duvelisib
  • +2 more
  • Frankston, Victoria, Australia
  • +4 more
2021-03-15
Mar 15, 2021
S
Withdrawn
  • Lymphoma
  • Duvelisib
  • +3 more
  • Miami, Florida
    (unnamed)
2021-03-15
Mar 15, 2021
G
Not yet recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-09-15
Sep 15, 2021
N
Recruiting
  • Recurrent Follicular Lymphoma
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-10-28
Oct 28, 2021
E
Recruiting
  • COVID-19
  • Duvelisib
  • Placebo
  • Atlanta, Georgia
  • +2 more
2020-12-11
Dec 11, 2020
N
Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-12-02
Dec 2, 2021
E
Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Duvelisib
  • Tisagenlecleucel
  • Atlanta, Georgia
  • +1 more
2021-10-05
Oct 5, 2021
D
Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
2021-11-22
Nov 22, 2021
D
Recruiting
  • Chronic Lymphocytic Leukemia
  • +7 more
  • Duvelisib
  • Nivolumab
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
2021-01-26
Jan 26, 2021
M
Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Basking Ridge, New Jersey
  • +6 more
2021-08-17
Aug 17, 2021
S
Withdrawn
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Duvelisib
  • Tempe, Arizona
  • +7 more
2021-03-15
Mar 15, 2021
S
Terminated
  • CD20+ Follicular Lymphoma
  • Duvelisib
  • +2 more
  • Los Angeles, California
  • +20 more
2021-03-15
Mar 15, 2021
S
Recruiting
  • Peripheral T-cell Lymphoma
  • Duvelisib
  • Duarte, California
  • +27 more
2021-09-30
Sep 30, 2021
M
Recruiting
  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas
  • Stanford, California
  • +10 more
2021-07-28
Jul 28, 2021